Tatiana Mushkarina

Ms. Tatiana Mushkarina

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Oncohematology
Verified
Journal Article
Open access
PDF file
LGL. Yu. Grivtsova
L. Yu. Grivtsova
TMTatiana Mushkarina
Tatiana Mushkarina
VLV. V. Lunin
V. V. Lunin
PZP. A. Zeynalova
P. A. Zeynalova
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
The article considers the features and possibilities of flow cytometric diagnostics of plasma cell neoplasms, taking into account the classification of lymphoid and hematopoietic tissue tumors of the World Health Organization, revision of 2017 and the NCCN clinical recommendations, 2021. Standardized flow cytometric protocols (the Euro-Flow conception) and algorithms for both the diagnosis of plasma cell tumors and the detection of minimal residual disease in plasma cell myeloma are described.

22 June 2023 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FAFiruza М. Abbasbeyli
Firuza М. Abbasbeyli
AFAlexandr A. Fedenko
Alexandr A. Fedenko
PZPervin A. Zeynalova
Pervin A. Zeynalova
TMTatiana Mushkarina
Tatiana Mushkarina
AMAnzhelika A. Melnikova
Anzhelika A. Melnikova
ГЮГривцова Людмила Юрьевна
Гривцова Людмила Юрьевна
Despite their B cell origin, Reed-Berezovsky-Sternberg tumor cells (RBS) in classic Hodgkin's lymphoma (cHL) demonstrate an absolutely unique phenotype. Immunohistochemistry of RBS cells is positive for CD15 antigen in most of cases, CD30, PAX-5; they do not express the T cell antigen CD3, В cell CD19, and in most cases are negative for the B cell antigen CD20, as well as for common leukocyte antigen CD45. Taking into account such unequivocal immunophenotype, RBS cells can be identified by multiparameter flow cytometry. Thus, J.R. Fromm et al. (2006, 2014) have convincingly shown the possibility to identify RBS cells in a puncture and/or biopsy sample of lymphatic nodes in cHL and were of the fair opinion that such rather simple and reproducible technique as flow cytometry could be an additional diagnostic instrument in cHL. We have tested the technique proposed by J.R. Fromm et al. for the assessment of lymphatic node involvement in cHL and used 8 to 10-parameter flow cytometry for detection RBS cells in cHL in 8 biopsy samples of a lymphatic node, and confirmed the feasibility to identify RBS cells by high performance flow cytometry. We also performed morphological and immunohistochemical assessment of the biopsy samples of lymphatic nodes from patients with suspected cHL. The study included clinical cases with immunohistochemically confirmed cHL (n = 8), and the control samples were from those with other diagnoses than Hodgkin's lymphoma. In all cases of cHL we found RBS cells. In future we plan to analyze larger case samples by flow cytometry.

12 September 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
FAF. M. Abbasbeyli
F. M. Abbasbeyli
AFA. A. Fedenko
A. A. Fedenko
PZP. A. Zeynalova
P. A. Zeynalova
RZR. F. Zibirov
R. F. Zibirov
VGV. N. Grinevich
V. N. Grinevich
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
Hodgkin’s lymphoma (HL) is a unique lymphoma of b-cell origin, the tumor cells of which have lost the expression of main b-cell antigens. The standard immunophenotype of the tumor substrate, according to immunohistochemical studies, is characterized by the expression of such markers as CD15, CD30 and PAX-5, while tumor cells have a negative expression of CD3, CD19 and in most cases also CD20 and CD45 (or express this antigen rather weakly). The knowledge gained in recent years has increased the effectiveness of diagnosis, prognosis and treatment of LH. Flow cytometry, as a method of immunophenotyping in classical LH, was practically not used due to the difficulty of distinguishing single reed–sternberg–berezovsky tumor cells (RSB) and the tumor microenvironment (reactive background), which is very rich in cellular elements and is represented by T cells, B cells, eosinophils, histiocytes and plasma cells. However, in the recent past, several studies have successfully attempted to identify rsb cells using multiparameter flow cytometry during aspiration with a thin needle or biopsy of lymph node tissue to confirm or supplement immunohistochemical staining during primary diagnosis. Taking into account the very characteristic immunophenotype of RSB cells, the flow cytometry may become an additional diagnostic method of classical LH in the future. In this review, we summarize the data on the possibility of using the flow cytometry as an additional clinical diagnostic option in the primary diagnosis of classical LH.

30 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
LGLyudmila Grivtsova
Lyudmila Grivtsova
AGAnastasia Glukhareva
Anastasia Glukhareva
AMAnzhelika Melnikova
Anzhelika Melnikova
TMTatiana Mushkarina
Tatiana Mushkarina
GAGrigoriy Afonin
Grigoriy Afonin
AKAndrey Kaprin
Andrey Kaprin
Background: The main type of treatment of unresectable NSCLC is chemoradiotherapy, which has a relatively high toxicity. One option allowing to reduce the toxicity of this approach may be immunocorrective therapy. The appointment of this type of treatment should be warranted in terms of patient’s immune system response. This confirms the importance of verifying systemic immune disorders in primary patients with NSCLC. Goal: To assess the features of the population of immune cells in peripheral blood in patients with stage IIIB, IIIC primary NSCLC and to identify any signs of secondary immunodeficiency in this cohort. Methods: We analyzed the frequencies of circulating T cells (CD3+, CD4+, CD8+), B-cells (CD19+), NK-cells (CD3-CD16+CD56+ cell), and NKT-cells (CD3+CD56+ cells) within CD45+ cells (lymphocytes) in 80 patients with stage IIIB-IIIC NSCLC, and in 40 healthy controls using eight-color flow cytometry. Results: In patients with stages IIIB-IIIC primary NSCLC, changes within immunocompetent blood cells were found. Moreover, it was unveiled that quantitative changes affected all major immunocompetent cells. A decrease in the proportion of CD4+ T cells and B lymphocytes and an increase in the number of NK and NKT cells were found. Also, an increase in the number of double-positive CD4+CD8+ T cells was revealed, as well as a significant increase in the proportion of B1a (CD5+CD19+) cells among B lymphocytes (qualitative disorders). Conclusion: The revealed multidirectional changes among immunocompetent peripheral blood cells in patients with locally advanced NSCLC (stages IIIB-IIIC) can be beyond doubt considered as signs of systemic immune disorders in this cohort (secondary immunodeficiency).

14 April 2022 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
IPI. A. Pasova
I. A. Pasova
LGL. Yu. Grivtsova
L. Yu. Grivtsova
TMTatiana Mushkarina
Tatiana Mushkarina
YGYu. V. Gelm
Yu. V. Gelm
SIS. A. Ivanov
S. A. Ivanov
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
Introduction. At present, in the light of impressive scientific achievements in tumor immunology, the question of the need for immunotherapeutic support in the treatment of cancer patients is especially relevant. Increasing attention is paid to the quality of life of patients receiving immunosuppressive therapy. However, the standards of immunotropic therapy in the complex and combined treatment of an oncological patient have not yet been developed. In the Russian Federation, more than 30 years ago, Timalin, a complex of peptides of thymic origin, was registered and approved for use in cancer patients.The aim of the study was to evaluate the potential of Timalin to improve the quality of life of cancer patients during standard therapy.Materials and methods. The study included 20 cancer patients, mostly with III–IV stages of the disease. All patients underwent a study of immunological status indicators before the start of therapy. The main indicators of cellular and humoral immunity were assessed: T-cells, B-cells, NKT-cells, activation markers, NK-cells, immunoregulatory index. All patients received Timalin. To assess the quality of life of patients, a questionnaire was used: EQ-5D before the start of Timalin immunotherapy, then once a week for one course lasting 1 month.Results. After 1 month 9 patients responded that their health status increased by 20 points (on a 100‑point scale), 3 patients by 15 points, and 8 patients by 10 points. Against the background of immunotherapeutic support, all patients noted a decrease in the level of side effects in the process of special treatment for the underlying disease.Conclusion. The article shows that before treatment, the indicators of the immune status and the condition of patients required immunocorrective therapy. Substantiated conclusions were made about the need to consider the inclusion of thymic peptides in the standards of care for cancer patients.

12 September 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
FAF. M. Abbasbeyli
F. M. Abbasbeyli
PZP. A. Zeynalova
P. A. Zeynalova
MVM. A. Vernyuk
M. A. Vernyuk
AFA. A. Fedenko
A. A. Fedenko
TMTatiana Mushkarina
Tatiana Mushkarina
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
Background. Classical Hodgkin’s lymphoma is a B-cell lymphoproliferative disease, the tumor substrate of which is Berezovsky–Reed–Sternberg cells, characterized by CD30, PAX-5, CD15 expression and the absence of CD3, CD45. In some cases, tumor cells express CD20. modern anticancer therapy has increased the survival probability for most patients, not only with early but also with advanced stages of classical Hodgkin’s lymphoma. Such successes are mainly due to the distribution of patients into prognostic groups and the choice of an appropriate treatment regimen. tumor infiltration of the bone marrow suggests assigning patients to the advanced stages group, followed by the choice of an intensive therapy program. Aim. To determine the bone marrow involvement frequency according to positron emission tomography combined with computed tomography (PET/CT), with 18F-fluorodeoxyglucose (FDG) and bone marrow trephine biopsy (bmtb), to compare the results obtained with primary tumor immunophenotype and bone marrow cellular composition, and to identify of prognostic risk factors. Materials and methods. The study included 107 patients with newly diagnosed classical Hodgkin’s lymphoma, who underwent a diagnostic examination at the moscow research institute of oncology named after P. A. Herzen – a branch of the National Medical Research Center for Radiology and the “Lapino” clinical Hospital from 2015 to 2022, followed by anticancer therapy and further follow-up. Morphology of the primary tumor biopsy specimen in all patients and immunohistochemical (IHC) study using a wide panel of monoclonal antibodies (CD15, CD30, CD3, CD45, CD20, PAX-5 anti-gens; in some cases epstein–barr virus proteins expression) in most cases were performed. All patients underwent a morphological and / or IHC study of BMTB and the majority underwent aspiration biopsy and PET/CT with 18F-FDG. Results. The most common histological variant of classical Hodgkin’s lymphoma was nodular sclerosis (86.9 %). The majority of patients (51.4 %) were assigned to the advanced stage prognostic group. bone marrow tumor infiltration was statistically significantly more frequently diagnosed during PET/CT with 18F-FDG compared with the results of the BMTB – in 27.1 % and 12.1 % of cases, respectively (p 0.05). when comparing the results of both diagnostic methods, it was found that in 17.1 % of cases, bone marrow infiltration, detected during PET/CT, was not confirmed by IHC examination of the trephine biopsy. In addition, it was found that the majority of cases with CD20+/± and CD15+/± expression in the primary tumor were observed in the group of patients without bone marrow involvement. when assessing the cellular composition of bone marrow aspirates, it was revealed that in patients with bone marrow tumor infiltration, an increase in cellularity and megakaryocytes number along with a decrease in the plasma cells number is observed. Conclusion. The results suggest further study of bone marrow immunomorphological features in order to identify prognostic factors and search for new therapeutic targets. a more extended analysis of bone marrow aspirate immunomor-phological characteristics using new modern diagnostic methods, minimal residual disease status as a surrogate marker seems to be relevant and necessary to confirm the depth of the antitumor response achieved. Detection of CD20+/±- and cd15+/±-Berezovsky–Reed–Sternberg cells according to primary tumor IHC analysis indicates a low probability of bone marrow tumor infiltration, but further analysis is required on a large clinical and laboratory material.